Zacks Investment Research downgraded shares of HUTCHISON CHINA/S (NASDAQ:HCM) from a hold rating to a sell rating in a research note issued to investors on Wednesday.
According to Zacks, “Hutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China MediTech Limited is based in Hong Kong. “
Separately, BidaskClub lowered HUTCHISON CHINA/S from a buy rating to a hold rating in a report on Saturday, November 10th.
NASDAQ:HCM traded down $1.72 during midday trading on Wednesday, reaching $31.22. The company had a trading volume of 209,803 shares, compared to its average volume of 864,021. The firm has a market cap of $4.38 billion, a PE ratio of -141.89 and a beta of 0.01. HUTCHISON CHINA/S has a 12-month low of $25.76 and a 12-month high of $42.25. The company has a current ratio of 4.67, a quick ratio of 4.55 and a debt-to-equity ratio of 0.06.
A number of large investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada purchased a new position in HUTCHISON CHINA/S in the first quarter valued at $199,000. Sumitomo Mitsui Trust Holdings Inc. raised its stake in HUTCHISON CHINA/S by 9.9% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 133,479 shares of the company’s stock valued at $4,297,000 after buying an additional 12,049 shares in the last quarter. GSA Capital Partners LLP raised its stake in HUTCHISON CHINA/S by 10.5% in the second quarter. GSA Capital Partners LLP now owns 222,345 shares of the company’s stock valued at $6,701,000 after buying an additional 21,077 shares in the last quarter. Renaissance Technologies LLC raised its stake in HUTCHISON CHINA/S by 375.0% in the third quarter. Renaissance Technologies LLC now owns 32,300 shares of the company’s stock valued at $1,040,000 after buying an additional 25,500 shares in the last quarter. Finally, Bellevue Group AG raised its stake in HUTCHISON CHINA/S by 10.0% in the second quarter. Bellevue Group AG now owns 332,536 shares of the company’s stock valued at $10,023,000 after buying an additional 30,116 shares in the last quarter. Hedge funds and other institutional investors own 11.79% of the company’s stock.
HUTCHISON CHINA/S Company Profile
Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments.
Recommended Story: Technical Analysis
Get a free copy of the Zacks research report on HUTCHISON CHINA/S (HCM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.